Comparing Prednisone and Methotrexate to Off-label Biologic Infliximab for Management of Ocular Uveitis: A Cost-minimization Analysis

Comparing Prednisone and Methotrexate to Off-label Biologic Infliximab for Management of Ocular Uveitis: A Cost-minimization Analysis

**Background:** Approximately 3.75% of cases of blindness in the United States are caused by uveitis. Incurred clinical costs and lost productivity related to vision loss in these cases totals $3.58 billion annually. **Objective:** To evaluate whether infliximab, a modern off-label biologic, is cos...

Full description

Bibliographic Details
Main Authors: William V. Padula, Miguel Cordero-Coma, Taygan Yilmaz, Michéal J. Gallagher, Jonathan D. Campbell
Format: Article
Language:English
Published: Columbia Data Analytics, LLC
Series:Journal of Health Economics and Outcomes Research
Online Access:http://jheor.scholasticahq.com/article/9895-comparing-prednisone-and-methotrexate-to-off-label-biologic-infliximab-for-management-of-ocular-uveitis-a-cost-minimization-analysis.pdf

Internet

http://jheor.scholasticahq.com/article/9895-comparing-prednisone-and-methotrexate-to-off-label-biologic-infliximab-for-management-of-ocular-uveitis-a-cost-minimization-analysis.pdf

Similar Items